This article is more than 5 years old. Information may no longer be current.
Continuation of bevacizumab with second-line chemotherapy extended survival in patients with metastatic colorectal cancer
Click Here to Manage Email Alerts
The addition of bevacizumab to standard chemotherapy during second-line treatment extended OS for patients with metastatic colorectal cancer who also received the combination during first-line treatment, according to results of a phase 3 study.
The trial was the first to evaluate the impact of continued VEGF inhibition with the addition of bevacizumab (Avastin, Genentech) to standard chemotherapy in second-line treatment for patients who also underwent the combination treatment in a first-line setting, researchers said.
Dirk Arnold, MD, director of the Hubertus Wald Tumor Center at the University Cancer Center of University Clinic Eppendorf in Hamburg, Germany, and colleagues enrolled 820 patients between February 2006 and June 2010. All patients had metastatic, inoperable colorectal cancer.
All patients had received either oxiliplatin- or irinotecan-based chemotherapy plus bevacizumab as first-line therapy and progressed within 3 months after discontinuation. After disease progression, the patients were randomized to a second round of treatment, this time with the opposite chemotherapy regimen, plus either bevacizumab (n=409) or placebo (n=411).
The primary endpoint was OS. Secondary endpoints included PFS, response rate and safety.
The patients assigned to bevacizumab in second-line treatment experienced statistically significant improvements in OS and PFS compared with the patients who received chemotherapy alone.
Median OS was 11.2 months in the bevacizumab arm vs. 9.8 months in the chemotherapy-alone arm (HR=0.81; 95% CI, 0.69-0.94; P=.0062). Median PFS was 5.7 months in the bevacizumab arm vs. 4.1 months in the chemotherapy-alone arm (HR=0.68; 95% CI, 0.59-0.78; P<.0001).
“The study confirms that the continuation of bevacizumab beyond progression while changing chemotherapy is beneficial for patients,” Arnold said during a press conference. “This clearly provides a new treatment option [in the second-line setting] for patients who have been pre-treated with a bevacizumab-combination regimen.”
The response rate was 5.4% in the bevacizumab group and 3.9% among the placebo group (P=.3113).
Patients in both arms tolerated the treatments well, the researchers said. Bevacizumab-related adverse events did not increase when continuing its use beyond progression, the researchers said.
“[The findings] provide an important new insight about the biology of advanced colorectal cancer, showing us that if the disease develops resistance to chemotherapy, it does not necessarily mean that tumors become resistant to anti-angiogenic therapy,” Arnold said in a press release.
Reference:
- Arnold D. Abstract #CRA3503.
Disclosure:
- The researchers report serving as a consultant or adviser for, as well as receiving research funding and honoraria from, Amgen, Baxter International, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Merck, Novartis, Pfizer, Roche and Sanofi.
Perspective
Back to Top
Tanios Bekaii-Saab, MD
Three studies presented at ASCO this year suggest that continuing VEGF inhibition (bevacizumab, regorafenib and aflibercept) following prior exposure/progression to/on bevacizumab may benefit patients with metastatic colorectal cancer. The benefit observed on all three studies is modest at best and will not have a major impact on the standard of practice given that most US physicians already use bevacizumab across lines of therapy. However, the findings presented by Arnold and colleagues likely will continue delaying usage of EGFR inhibitors in KRAS wild-type patients and now aflibercept to later lines of therapy given their more noticeable toxicities.
Perspective
Back to Top
Richard M. Goldberg, MD
This Roche-funded study is long overdue. For years, clinicians have relied on data from the retrospective Genentech-funded BRITE registry reported in the Journal of Clinical Oncology by Grothey and colleagues in 2008 to make a decision about whether to continue bevacizumab with subsequent lines of chemotherapy after progression on initial chemotherapy administered with bevacizumab. That report suggested a major survival benefit to continuing bevacizumab, and the Arnold data show us that the BRITE data were misleading. Interpretation of the TML study is complicated by the design, which permitted enrolling physicians to use any of three initial irinotecan or oxaliplatin and 5-FU therapies and then crossed patients over to the reciprocal chemotherapy. It is likely that the interactions between bevacizumab and irinotecan are not the same as the those with oxaliplatin. In any case, the median OS benefit for continuing bevacizumab in the heterogeneously treated study population is a modest 5 weeks. The good news is that additive toxicity was also modest. It is likely that this study’s outcome will not change oncologists’ behaviors much. Many US oncologists already use bevacizumab upon progression, although a substantial number do not. In many countries outside the United States, the cost/benefit ratio will exceed the threshold for what nationalized health care systems consider for coverage and its use will not be supported. Whether to continue the agent across lines of therapy remains a matter of perceived value and societal values, as well as the patient’s, payer’s and physician’s opinions about the modest median survival benefit. The positive spin put on the pre-ASCO press releases from Roche leading up to this meeting suggest that the results will be used enthusiastically to market the continuation strategy. My own degree of enthusiasm about these data remains tepid.
Click Here to Manage Email Alerts